---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-044260"
form_type: "8-K/A"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2026-06-18T20:04:56+00:00"
generated_at: "2026-06-18T20:11:36.152075+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Esperion acquires Corstasis for $83.4M, financed via $25M loan and $50M royalty sale

## Summary
- Total acquisition cost $83.4M: $77.5M cash to Corstasis plus $5.9M direct transaction costs.
- Acquired developed product intangible Enbumyst valued at $77.1M, amortized over 10 years.
- Financing: $25M term loan at 9.75% (effective ~10.5%) and $50M royalty sale to Athyrium with $100M cap.
- Pro forma net loss for 2025 increases to $47.1M from $22.7M historical; no goodwill recognized.

## SEC filing metadata
- accession: 0001628280-26-044260
- form_type: 8-K/A
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2026-06-18T20:04:56+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828026044260/0001628280-26-044260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828026044260/espr-20260402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-044260
- JSON: https://secwatch.observer/filing/0001628280-26-044260.json
- Plain text: https://secwatch.observer/filing/0001628280-26-044260.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.